TerminatedPhase 2NCT00902525
Zevalin Twice in Aggressive Non-Hodgkin Lymphoma
Studying Aggressive B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
- Principal Investigator
- Barbara Botto, MD, MDSCDO Ematologia AOU San Giovanni Battista Torino
- Intervention
- 90Y-Ibritumomab Tiuxetan(drug)
- Enrollment
- 25 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2008 – 2011
Study locations (12)
- Divisione di Ematologia Ospedale SS Antonio e Biagio, Alessandria, AL, Italy
- Istituto di Ematologia e Oncologia Medica L. Seragnoli Policlinco S. Orsola, Bologna, BO, Italy
- Divisione di Ematologia, Spedali Civili, Brescia, BS, Italy
- Divisione di Ematologia Ospedale Centrale di Bolzano, Bolzano, BZ, Italy
- Divisione di Ematologia Ospedale Businco, Cagliari, CA, Italy
- Divisione di Ematologia Ospedale Cardinale Panico, Tricase, LE, Italy
- Divisione di Ematologia Ospedale Niguarda Cà Granda, Milan, MI, Italy
- Divisione di Oncoematologia IRCC, Candiolo, TO, Italy
- Divisione di Ematologia Istituto Nazionale Fondazione Pascale, Naples, Italy
- SC Ematologia Ospedale Maggiore Università Avogadro, Novara, Italy
- Divisione di Oncoematologia Azienda Ospedalier S. Maria, Terni, Italy
- SCDO Ematologia 2 AOU San Giovanni Battista, Turin, Italy
Collaborators
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00902525 on ClinicalTrials.govOther trials for Aggressive B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07474051Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsAvenCell Therapeutics, Inc.
- RECRUITINGEARLY PHASE1NCT07344818An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell LymphomaPeking University People's Hospital
- RECRUITINGPHASE2NCT07097363Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2, PHASE3NCT07168980Chemotherapy With Rituximab for Aggressive B-NHL in Children and AdolescentsChildren's Cancer Group, China
- RECRUITINGPHASE2NCT06996132Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1, PHASE2NCT06536049Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaYazeed Sawalha
- RECRUITINGPHASE2NCT06834373Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyMayo Clinic